Aimmune Therapeutics Inc. (AIMT)

22.43
NASDAQ : Health Technology
Prev Close 21.79
Day Low/High 21.81 / 22.47
52 Wk Low/High 16.95 / 36.12
Avg Volume 516.30K
Exchange NASDAQ
Shares Outstanding 62.67M
Market Cap 1.37B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Interesting AIMT Put And Call Options For November 17th

Interesting AIMT Put And Call Options For November 17th

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Participate In Three Investor Conferences In September

Aimmune Therapeutics To Participate In Three Investor Conferences In September

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at...

Aimmune Therapeutics To Present At The 2017 Wedbush PacGrow Healthcare Conference On Wednesday, August 16th

Aimmune Therapeutics To Present At The 2017 Wedbush PacGrow Healthcare Conference On Wednesday, August 16th

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the 2017 Wedbush...

Aimmune Therapeutics Announces Second Quarter 2017 Financial Results

Aimmune Therapeutics Announces Second Quarter 2017 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017.

Aimmune Therapeutics' Investigational Treatment For Peanut Allergy Featured In Science Translational Medicine Publication On Discovery Of New TH2 Cell Subset Specific To Allergy

Aimmune Therapeutics' Investigational Treatment For Peanut Allergy Featured In Science Translational Medicine Publication On Discovery Of New TH2 Cell Subset Specific To Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its investigational treatment for peanut allergy, AR101, was highlighted...

Aimmune Therapeutics Enrolls First Patient In ARTEMIS (ARC010) European Phase 3 Clinical Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics Enrolls First Patient In ARTEMIS (ARC010) European Phase 3 Clinical Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the European Phase 3 ARTEMIS (ARC010) clinical trial of AR101 for treatment of peanut allergy.

Aimmune Therapeutics Stock Sees Short Interest Move 10.8% Higher

The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 459,986 share increase in total short interest for Aimmune Therapeutics Inc , to 4,721,762, an increase of 10.79% since 05/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Interesting AIMT Put And Call Options For August 18th

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data At 2017 European Academy Of Allergy And Clinical Immunology (EAACI) Congress

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today reported findings from pre-randomization, preliminary clinical data collected from the...

Aimmune Therapeutics To Present Data On Peanut Allergy In Europe At The European Academy Of Allergy And Clinical Immunology (EAACI) Congress 2017

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, announced today that it will present data during poster sessions on Tuesday, June 20, at the...

Aimmune Therapeutics Reports On Up-Dosing In Its Ongoing Phase 3 PALISADE Trial Of AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that, in the ongoing Phase 3 PALISADE trial of AR101, more than 97 percent of...

Aimmune Therapeutics To Present At The Goldman Sachs 38th Annual Global Healthcare Conference On Thursday, June 15th

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the Goldman Sachs...

Aimmune Therapeutics Cuts Ribbon On Commercial Manufacturing Facility To Support Potential Launch Of Treatment For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today hosted a ribbon-cutting ceremony to celebrate the completion of its commercial...

Aimmune Therapeutics Enters Oversold Territory (AIMT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aimmune Therapeutics Enrolls First Patient In RAMSES (ARC007), A Phase 3 Clinical Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy.

Aimmune Therapeutics To Present At The Bank Of America Merrill Lynch Healthcare Conference On Tuesday, May 16

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that CEO...

Aimmune Therapeutics Announces First Quarter 2017 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced...

Aimmune Therapeutics Becomes Oversold (AIMT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aimmune Therapeutics Appoints Eric Bjerkholt As Chief Financial Officer

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer.

First Week of AIMT May 19th Options Trading

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new May 19th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics Announces Fourth Quarter And Full Year 2016 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced financial...

Aimmune Therapeutics To Release Fourth Quarter And Full Year 2016 Financial Results On Wednesday, March 15, 2017

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its financial results for the fourth quarter and full year 2016 will be...

Aimmune Therapeutics Presents Clinical Data On Phase 3 Screening And Phase 2 Adherence For AR101 For Peanut Allergy At The 2017 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, announced clinical data presented today at the 2017 American Academy of Allergy, Asthma &...

Aimmune Therapeutics To Participate In Two Upcoming Investor Conferences In March

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that CEO...

Aimmune Therapeutics To Present AR101 Clinical Data In Peanut Allergy At The 2017 American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that new...

Aimmune Therapeutics Provides Update On Ongoing AR101 Phase 3 Program For Peanut Allergy Based On FDA Feedback

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced an AR101 Phase 3 program update, based on recent feedback from the U.

Aimmune Therapeutics Becomes Oversold (AIMT)

Aimmune Therapeutics Becomes Oversold (AIMT)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Aimmune Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference

Aimmune Therapeutics To Present At The 35th Annual J.P. Morgan Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that CEO...

Aimmune Therapeutics Appoints Scientific Advisory Board Of World-Renowned Food Allergy Experts

Aimmune Therapeutics Appoints Scientific Advisory Board Of World-Renowned Food Allergy Experts

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced the...

Aimmune Therapeutics Completes Global Enrollment Of Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics Completes Global Enrollment Of Phase 3 PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ ( Characterized Oral Desensitization Immuno Therapy) treatments for life-threatening food allergies, today announced that it...